Osteoarticular Infection Clinical Trial
Official title:
Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements
Osteoarticular infections associated with hip and knee prostheses require optimal surgical and medical management to maximize the rate of therapeutic success. Antibiotic therapy should be administered for a period of 12 weeks. Tolerance problems, difficulties in maintaining compliance over 12 weeks, bacterial multidrug resistance and sometimes intravenous administration are the main obstacles to appropriate antibiotic therapy and to limiting iatrogenicity. Dalbavancin is an antibiotic derived from teicoplanin (glycopeptide) with a long half-life, of punctual parenteral administration without a central line, active on staphylococci, and well tolerated. The data in the literature concerning its efficacy in Osteoarticular infections associated with hip and knee prostheses are limited and heterogeneous. Investigators would like to describe its efficacy in a homogeneous series of patients in terms of the type of infection, their surgical management and the methods of administration of the product in order to extend its use.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01500837 -
Treatment of Methicillin-sensitive Staphylococcus Aureus (MSSA)
|
N/A | |
| Completed |
NCT01815541 -
Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study
|
Phase 2 | |
| Completed |
NCT02599493 -
EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin
|
Phase 4 |